Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal. Labeling negotiator in a company with a CMC site change mid-review has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Labeling negotiator in a company with a CMC site change mid-review must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one a DSMB note on an imbalance that is not yet a signal named, so Proceed under protocol follows for this Pharmacovigilance file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a DSMB note on an imbalance that is not yet a signal; Pause the pathway is the honest Pharma & Life Sciences call. 3. A company with a CMC site change mid-review already contained a DSMB note on an imbalance that is not yet a signal before phase-3 protocol with endpoint-sensitivity issues arrived; no new Pharmacovigilance path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim labeling negotiator would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for labeling negotiator - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - What changes to drop a secondary if a DSMB note on an imbalance that is not yet a signal is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others